2-isopropyl-4-methoxyquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-isopropyl-4-methoxyquinoline
• 英文别名: 4-Methoxy-2-propan-2-ylquinoline
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: KXDNANNOZNQZHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-甲氧基喹啉 、 异丁酸 在 2-吡啶甲酸 、 ferrous(II) sulfate heptahydrate 、 sodium bromate 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 24.0h， 以72%的产率得到2-isopropyl-4-methoxyquinoline
  参考文献：
  名称：

  Ligand-Accelerated Iron Photocatalysis Enabling Decarboxylative Alkylation of Heteroarenes

  摘要：

  A mild, practical protocol for the decarboxylative alkylation of heteroarenes has been accomplished via iron photocatalysis. A diverse range of carboxylic acids readily undergo oxidative decarboxylation and then couple with a broad array of heteroarenes in this transformation. The photoexcited state lifetimes of iron complexes are typically much shorter than those of iridium and ruthenium complexes. Here we describe our effort on iron photocatalysis by utilizing the intramolecular charge transfer pathway of iron-carboxylate complexes.

  DOI：

  10.1021/acs.orglett.9b01439

文献信息

• Photoelectrochemical C−H Alkylation of Heteroarenes with Organotrifluoroborates
  作者：Hong Yan、Zhong‐Wei Hou、Hai‐Chao Xu

  DOI：10.1002/anie.201814488

  日期：2019.3.26

  A photoelectrochemical method for the C−H alkylation of heteroarenes with organotrifluoroborates has been developed. The merger of electrocatalysis and photoredox catalysis provides a chemical oxidant‐free approach for the generation and functionalization of alkyl radicals from organotrifluoroborates. A variety of heteroarenes were functionalized using primary, secondary, and tertiary alkyltrifluoroborates

  已经开发了一种用有机三氟硼酸盐进行杂芳烃的CH烷基化的光电化学方法。电催化和光氧化还原催化的合并为有机三氟硼酸盐的烷基自由基的产生和功能化提供了一种无化学氧化剂的方法。使用具有出色的区域选择性和化学选择性的伯，仲和叔烷基三氟硼酸酯对各种杂芳烃进行功能化。
• [EN] BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF- DOLLAR G(A) CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES<br/>[FR] DERIVES D'ACIDE BARBITURIQUE UTILISES COMME INHIBITEURS DE L'ENZYME DE CONVERSION DU TNF- DOLLAR G(A) (TACE) ET/OU DE METALLOPROTEINASES MATRICIELLES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003053940A1

  公开（公告）日：2003-07-03

  The present application describes novel barbituric acid derivatives of formula (I), or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, W, Z, U?a, Xa, Ya, and Za¿ are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了新的巴比妥酸衍生物的公式（I），或其药学上可接受的盐或前药形式，其中A、B、L、R1、W、Z、Ua、Xa、Ya和Za在本说明中有定义，它们可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES
  申请人：Duan Jingwu

  公开号：US20070167451A1

  公开（公告）日：2007-07-19

  The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了新型的巴比妥酸衍生物式I：或其药物可接受的盐或前药形式，其中A、B、L、R1、R2、R3、R4、R5、n、W、U、X、Y、Z、Ua、Xa、Ya和Za在本说明书中有定义，它们可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels
  申请人：Vertexs Pharmaceuticals Incorporated

  公开号：US20150005304A1

  公开（公告）日：2015-01-01

  The invention relates to pyran spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及一种吡喃螺环哌啶酰胺化合物，可用作离子通道的抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法。
• Heterocyclic compounds as anti-viral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11420976B2

  公开（公告）日：2022-08-23

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 其可抑制呼吸道合胞病毒（RSV）或HMPV。本发明进一步涉及包含上述化合物的药物组合物，用于给患有 RSV 或 HMPV 感染的受试者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 RSV 或 HMPV 感染的方法。